Breast Cancer Task Force Must Take More Active Role In RFP Development, New Chairman Insists
In Brief: FDA To Review Preclinical Testing, Phase I Protocols At Open Advisory Group Meeting
FDA Pettiness Holds Up Trials with Promising Anticancer Drugs
FDA Proposes Guidelines For Testing New Anticancer Drugs
Breast Cancer Progress Report Summaries
Shubick Committee Support New System for NCU Review, Action On Chemicals
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
